Strategic partnerships Circio is actively forming collaborations with specialized biotech firms and academic institutions (Avenue Biosciences, Tcelltech, GenAssist, Karolinska Institute) to advance circVec RNA platforms and targeted gene therapies, indicating a receptive path for co-development, license, or production partnerships.

Platform monetization The circVec circular RNA expression technology and circVec-enhanced AAV vectors are central assets with ongoing collaborations for in vivo and cell therapy applications, presenting opportunities for licensing deals, upfront milestones, and milestone-driven collaborations.

Indication focus A strong emphasis on heart disease gene therapies and oncology vaccine programs (mutant RAS) suggests cross-sell opportunities with cardiovascular and cancer-focused CROs, contract research, or joint development arrangements targeted at these high-need areas.

Clinical and financing runway With a NOK 300m funding round extending runway to 2030 and phase II/IND-enabling development plans, there is potential for strategic investment conversations, CRO partnerships for later-stage trials, and scalable manufacturing collaborations to support clinical timelines.

Global collaboration footprint Active international partnerships across the US, Norway, Germany, China, and Finland indicate a global sales approach; identify regional stakeholders, regulatory consultants, and local partners to accelerate market access, tech transfer, and co-commercialization discussions.